Massive 146% Income Rise At Fujisawa

14 November 1994

Fujisawa of Japan revealed a 146% increase in net income for the first six months ended September 30, 1994 to 4.5 billion yen ($45.8 million). The company said that the significant increase was a result of a decline in the extraordinary loss reserved in the allowance for the loss of Fujisawa USA, and also in the amount of income taxes.

Operating income was ahead 17.9% to 11.6 billion yen due to "an efficient use and curtailment of expenditures within the company." Recurring profits were up 5.1% to 12.2 billion yen.

Total net sales for the first six months were 117.5 billion yen ($1.19 billion), advancing just under 1% on the like, year-earlier period. Of this total, ethical sales amounted to 100.5 billion yen, up 1.8%, consumer products were virtually flat at 7.4 billion yen, sales of medical equipment and supplies declined 47.6% to 789 million yen and sales of chemicals and animal health products dropped 3.5% to 6.7 billion yen.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight